Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in Biomarker-Selected Advanced NSCLC
NCT04612673Phase 2Unknown
- Sponsor
- China Medical University
- Start
- Nov 2020
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by China Medical University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04612673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612673.